← Back to All US Stocks

AdaptHealth Corp. (AHCO) Stock Fundamental Analysis & AI Rating 2026

AHCO Nasdaq Services-Home Health Care Services DE CIK: 0001725255
Recently Updated • Analysis: May 7, 2026 • SEC Data: 2026-03-31
Combined AI Rating
SELL
86% Confidence
AGREEMENT
STRONG SELL
88% Conf
SELL
84% Conf

📊 AHCO Key Takeaways

Revenue: $819.8M
Net Margin: -2.0%
Free Cash Flow: $-27.5M
Current Ratio: 0.92x
Debt/Equity: 1.21x
EPS: $-0.12
AI Rating: STRONG SELL with 88% confidence
AdaptHealth Corp. (AHCO) receives a SELL rating with 86% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $819.8M, net profit margin of -2.0%, and return on equity (ROE) of -1.1%, AdaptHealth Corp. demonstrates mixed fundamentals in the Services sector. Below is our complete AHCO stock analysis for 2026.

Is AdaptHealth Corp. (AHCO) a Good Investment?

Claude

AdaptHealth is fundamentally distressed with negative profitability (-2.0% net margin), critical debt servicing issues (0.1x interest coverage), and negative free cash flow despite positive operating cash flow. Weak liquidity (0.92x current ratio, only $48M cash) combined with flat revenue growth and $1.8B long-term debt creates severe financial stress.

ChatGPT

AdaptHealth shows meaningful cash generation, but its core earnings profile remains weak: revenue is slightly declining, operating margin is thin at 2.8%, and net income remains negative. Financial risk is elevated by high leverage and sub-1x interest coverage, which limits resilience if operating performance does not improve. The business is not fundamentally broken, but current profitability and balance-sheet pressure outweigh the cash flow positives.

Why Buy AdaptHealth Corp. Stock? AHCO Key Strengths

Claude
  • + Positive operating cash flow of $93.7M demonstrates core business generates cash
  • + Established revenue base of $819.8M in essential home health care services
  • + Debt-to-equity ratio of 1.21x is manageable relative to highly leveraged peers
ChatGPT
  • + Strong operating cash flow generation of $601.77M supports debt service and reinvestment capacity
  • + Positive free cash flow of $219.38M indicates the business can still produce cash after capital spending
  • + Large asset and equity base provides some balance-sheet support despite current earnings weakness

AHCO Stock Risks: AdaptHealth Corp. Investment Risks

Claude
  • ! Interest coverage ratio of 0.1x indicates company cannot service debt from operating income—critical solvency risk
  • ! Negative free cash flow of -$27.5M despite positive operating cash flow due to high capex, signaling cash burn
  • ! Liquidity crisis with current ratio of 0.92x and minimal cash reserves ($48M) creating refinancing pressure
  • ! Persistent unprofitability with -2.0% net margin and negative ROE/ROA indicating structural operational challenges
  • ! Revenue stagnation (-0.5% YoY) with no visible growth trajectory in mature market
ChatGPT
  • ! Negative net income and -2.2% net margin indicate weak underlying profitability
  • ! Interest coverage of 0.9x suggests operating income is not comfortably covering interest expense
  • ! Revenue declined 0.5% year over year, raising concern about growth quality and operating leverage

Key Metrics to Watch

Claude
  • * Interest coverage ratio trajectory—must improve above 1.0x for viability
  • * Free cash flow and cash balance—monitor for covenant breaches or refinancing needs
  • * Net margin expansion—requires operational improvements to achieve profitability
  • * Revenue growth acceleration—flat performance is unsustainable given debt burden
ChatGPT
  • * Interest coverage and long-term debt reduction
  • * Operating margin and free cash flow sustainability

AdaptHealth Corp. (AHCO) Financial Metrics & Key Ratios

Revenue
$819.8M
Net Income
$-16.0M
EPS (Diluted)
$-0.12
Free Cash Flow
$-27.5M
Total Assets
$4.4B
Cash Position
$48.0M

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

AHCO Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin 0.7%
Net Margin -2.0%
ROE -1.1%
ROA -0.4%
FCF Margin -3.4%

AHCO vs Services Sector: How AdaptHealth Corp. Compares

How AdaptHealth Corp. compares to Services sector averages

Net Margin
AHCO -2.0%
vs
Sector Avg 10.0%
AHCO Sector
ROE
AHCO -1.1%
vs
Sector Avg 16.0%
AHCO Sector
Current Ratio
AHCO 0.9x
vs
Sector Avg 1.5x
AHCO Sector
Debt/Equity
AHCO 1.2x
vs
Sector Avg 0.7x
AHCO Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is AdaptHealth Corp. Stock Overvalued? AHCO Valuation Analysis 2026

Based on fundamental analysis, AdaptHealth Corp. shows some fundamental concerns relative to the Services sector in 2026.

Return on Equity
-1.1%
Sector avg: 16%
Net Profit Margin
-2.0%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
1.21x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

AdaptHealth Corp. Balance Sheet: AHCO Debt, Cash & Liquidity

Current Ratio
0.92x
Quick Ratio
0.71x
Debt/Equity
1.21x
Debt/Assets
65.8%
Interest Coverage
0.05x
Long-term Debt
$1.8B

AHCO Revenue & Earnings Growth: 5-Year Financial Trend

AHCO 5-year financial data: Year 2021: Revenue $2.5B, Net Income -$21.3M, EPS $-0.95. Year 2022: Revenue $3.0B, Net Income -$161.6M, EPS $-3.08. Year 2023: Revenue $3.2B, Net Income $156.2M, EPS $0.67. Year 2024: Revenue $3.3B, Net Income $69.3M, EPS $0.33. Year 2025: Revenue $3.3B, Net Income -$678.9M, EPS $-5.31.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: AdaptHealth Corp.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.31 indicates the company is currently unprofitable.

AHCO Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-3.4%
Free cash flow / Revenue

AHCO Quarterly Earnings & Performance

Quarterly financial performance data for AdaptHealth Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $777.9M -$7.2M $-0.05
Q3 2025 $805.9M $22.9M $0.15
Q2 2025 $800.4M $7.5M $0.05
Q1 2025 $777.9M -$2.1M $-0.02
Q3 2024 $804.0M $22.9M $0.15
Q2 2024 $793.3M $14.0M $0.03
Q1 2024 $744.6M -$2.1M $-0.02
Q3 2023 $756.5M $16.1M $0.11

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

AdaptHealth Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$93.7M
Cash generated from operations
Capital Expenditures
$121.2M
Investment in assets
Dividends
None
No dividend program

AHCO SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for AdaptHealth Corp. (CIK: 0001725255)

📋 Recent SEC Filings

Date Form Document Action
May 5, 2026 10-Q ahco-20260331.htm View →
May 5, 2026 8-K ahco-20260505.htm View →
Apr 28, 2026 DEF 14A ahco-20260428.htm View →
Apr 13, 2026 8-K adapthealth-8xkboafacility.htm View →
Mar 23, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about AHCO

What is the AI rating for AHCO?

AdaptHealth Corp. (AHCO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are AHCO's key strengths?

Claude: Positive operating cash flow of $93.7M demonstrates core business generates cash. Established revenue base of $819.8M in essential home health care services. ChatGPT: Strong operating cash flow generation of $601.77M supports debt service and reinvestment capacity. Positive free cash flow of $219.38M indicates the business can still produce cash after capital spending.

What are the risks of investing in AHCO?

Claude: Interest coverage ratio of 0.1x indicates company cannot service debt from operating income—critical solvency risk. Negative free cash flow of -$27.5M despite positive operating cash flow due to high capex, signaling cash burn. ChatGPT: Negative net income and -2.2% net margin indicate weak underlying profitability. Interest coverage of 0.9x suggests operating income is not comfortably covering interest expense.

What is AHCO's revenue and growth?

AdaptHealth Corp. reported revenue of $819.8M.

Does AHCO pay dividends?

AdaptHealth Corp. does not currently pay dividends.

Where can I find AHCO SEC filings?

Official SEC filings for AdaptHealth Corp. (CIK: 0001725255) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AHCO's EPS?

AdaptHealth Corp. has a diluted EPS of $-0.12.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is AHCO a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, AdaptHealth Corp. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is AHCO stock overvalued or undervalued?

Valuation metrics for AHCO: ROE of -1.1% (sector avg: 16%), net margin of -2.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy AHCO stock in 2026?

Our dual AI analysis gives AdaptHealth Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is AHCO's free cash flow?

AdaptHealth Corp.'s operating cash flow is $93.7M, with capital expenditures of $121.2M. FCF margin is -3.4%.

How does AHCO compare to other Services stocks?

Vs Services sector averages: Net margin -2.0% (avg: 10%), ROE -1.1% (avg: 16%), current ratio 0.92 (avg: 1.5).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% CTAS 92% CRUS 92% CRMD 92% CRDO 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 7, 2026 | Data as of: 2026-03-31 | Powered by Claude AI